Insulin Resistance Market Segmentation:
- By Drug Class
- Biguanides
- Thiazolidinediones
- DPP-4 Inhibitors
- SGLT-2 Inhibitors
- GLP-1 Receptor Agonists
- Others
- By Route of Administration
- Oral
- Injectable
- Inhalable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Diabetes Clinics/Centers
- Regions
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The Insulin Resistance Market is valued at USD 23.4 billion in 2023. current market size of the genital herpes industry is estimated at around US$ 5.2 billion in 2023.
Rising prevalence of diabetes and obesity, development of novel drugs and devices, favorable policies, technological integration, improving diagnosis, patient awareness programs.
Stringent regulatory requirements, long product development timelines, pricing pressure, side effects, limited awareness in developing regions.
Biguanides drugs like metformin are the leading segment owing to widespread use as first line of treatment.
Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Abbott, Roche, Merck, Medtronic, J&J.
The market is projected to reach USD 32.8 billion by 2030 from USD 23.4 billion in 2023, growing at a CAGR of 4.9% during the forecast period.
Rising prevalence of diabetes and obesity, unhealthy lifestyles, advancing pharmaceutical R&D, favorable reimbursement policies, integration of digital technology.